Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

GB:0QNA Stock Latest News

Company AnnouncementsBasilea boosts 2026 profit outlook and advances late-stage anti-infective pipeline5d ago

The FlyBasilea price target raised to CHF 110 from CHF 105 at H.C. Wainwright1M ago
Company AnnouncementsBasilea Pharmaceutica Earnings Call Signals Confident Growth2M ago
Company AnnouncementsBasilea lifts 2026 profit outlook as anti-infectives pipeline and Cresemba sales power H1 results2M ago
Company AnnouncementsBasilea Wins More BARDA Funding for Novel Oral Antibiotic Targeting Drug‑Resistant UTIs2M ago

BARDA injects $30 million into Basilea’s phase 3 antifungal program

Company AnnouncementsBARDA injects $30 million into Basilea’s phase 3 antifungal program3M ago

Company AnnouncementsBasilea Wins Fresh BARDA Funding for Novel Oral Antibiotic to Tackle Drug-Resistant UTIs5M ago

Company AnnouncementsBasilea Wins CARB-X Funding Boost for First-in-Human Trial of Novel Antibiotic BAL24206M ago

Company AnnouncementsBasilea Wins BARDA Funding to Advance Novel Oral Antibiotic for Drug-Resistant UTIs8M ago
Company AnnouncementsBasilea Pharmaceutica Earnings Call Highlights Pipeline Push8M ago
Company AnnouncementsBasilea boosts revenues, triples net cash as anti‑infective pipeline advances8M ago
RatingsBasilea Pharmaceutica’s Strategic AI Partnership and Antifungal Growth Drive Buy Rating10M ago

Basilea Achieves Sales Milestone with Cresemba in Europe

Company AnnouncementsBasilea Achieves Sales Milestone with Cresemba in Europe12M ago

Company AnnouncementsBasilea Secures BARDA Funding for Novel Antibiotic Development1y ago

RatingsBasilea Pharmaceutica’s Strategic Expansion and Financial Backing Earns Buy Rating1y ago

Company AnnouncementsBasilea Secures Additional BARDA Funding for Antifungal Development1y ago
Company AnnouncementsBasilea Pharmaceutica’s Earnings Call Highlights Growth and Challenges1y ago
Company AnnouncementsBasilea Pharmaceutica Reports Strong Financial Growth and Strategic Milestones in H1 20251y ago
Company AnnouncementsBasilea Pharmaceutica Expands Pipeline with New Antibiotic License1y ago

Basilea Pharmaceutica’s Promising Future: Buy Rating Backed by Fosmanogepix Potential and Robust Valuation

RatingsBasilea Pharmaceutica’s Promising Future: Buy Rating Backed by Fosmanogepix Potential and Robust Valuation1y ago

RatingsBasilea Pharmaceutica Receives Buy Rating Backed by U.S. Government Funding and Promising Drug Developments1y ago

Company AnnouncementsBasilea Secures $39 Million BARDA Funding for Antifungal Drug Development1y ago